JMP Securities downgraded Spruce Biosciences (SPRB) to Market Perform from Outperform without a price target The firm is stepping to the sidelines after tildacerfont missed in the Phase 2b CAHmelia-204 trial. Despite some evidence of more effective twice-daily doses in the Phase 2 CAHptain-205 trial, the data apparently are not convincing enough for further investment in congenital adrenal hyperplasia, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences Inc trading resumes
- Spruce Biosciences Inc trading halted, news pending
- Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint
- Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?
- Spruce Biosciences Reports Q3 2024 Earnings and Updates